Introduction assay (Amersham International plc, Little Chalfont, Adrenomedullin (AM) has vasodilator effects in a
Bucks, UK). number of vascular beds 1 with possibly the most marked actions being in the pulmonary vasculatStatistical analyses ure.
2 Previous studies have shown AM to be synthesised by cultured endothelial cells (EC), includOne-way analysis of variance and Tukey-Kramer ing human umbilical vein and bovine aorta (BAEC), multiple comparisons tests were used to determine as well as by rat aortic smooth muscle cells.
3-4 AM the significance of differences between data. has specific effects on both endothelial cells and smooth muscle cells via receptor-mediated increases
Results
in cyclic AMP (cAMP) production. 1, 5 We have previously reported that AM potentiates the calcium Treatment of BAEC for 6 h with AM (100 nM) response provoked by bradykinin stimulation in reduced ET-1 release to 71.6 ± 6.3% of basal EC.
6 This is consistent with reports of its ability to (P Ͻ 0.001) (Figure 1 ). BKN (1 M) also caused a stimulate nitric oxide (NO) release. In addition, we smaller but significant reduction in ET-1 release have shown that AM reduces the production of the (P Ͻ 0.01; relative to AM effect) which was neverpotent vasoconstrictor endothelin-1 (ET-1) by EC in theless significantly different from basal ET-1 culture.
7 In the present study we have examined the release (P Ͻ 0.001). Treatment with AM (100 nM) effects of bradykinin (BKN) and AM, alone and in combination, on ET-1 production by BAEC and cAMP generation in these cells.
Experimental
Cell culture: Cells were routinely cultured in DMEM containing 10% FBS and were washed twice in serum-free medium prior to use.
ET-1 release:
Cells were incubated for 6 h in the presence or absence of AM or BKN, and a direct radioimmunoassay was used to measure ET-1 release into BAEC conditioned medium. 8 cAMP assays: Cells were incubated in the presence or absence of AM or BKN for 15 min in medium containing the phosphodiesterase inhibitor IBMX (1 mM). cAMP determinations were carried out in by additive increases in cAMP production. This suggests that AM and BKN activate convergent pathways to promote vasodilation, in part by inducing NO release, and also by causing a reduction in ET-1 release by these cells.
Our studies to date have uncovered a number of interactions which could have a significant bearing on the roles of AM in vivo. It has also been shown that AM is able to reverse the vasoconstricting effects of ET-1 in porcine coronary artery in vitro. 10 Thus, the interplay between AM (vasodilator) and ET-1 (vasoconstrictor) systems may be pivotal in the local regulation of vascular homeostasis. Furthermore, disruptions of this fine balance could play a part in pathologies such as hypertension and atherosclerosis. 6 Here we show a
